Promis NeurosciencesPMN
13F holders, Q3 2024 (September 30)18holders +2
4new positions
3sold out
$1.25avg. 13F price*
At the end of Q3 2024, 18 institutions reported holding Promis Neurosciences Inc. (PMN) in their 13F filings, up 2 from Q2 2024. 4 opened new positions and 3 sold out. The largest holders were Great Point Partners LLC ($3.5M), Armistice Capital, LLC ($3.3M) and Sphera Funds Management LTD. ($2.4M).
- Company
- Promis Neurosciences Inc.
- CUSIP
- 74346M406
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $7.6M |
| Exits | 3 | $44K |
All 13F filers, Q2 2024 → Q3 2024: 6,702,943 shares bought and 264,755 shares sold, net +6,438,188 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Great Point Partners LLC | 1.05% | New | 2,790,698 | $3.5M |
| Armistice Capital, LLC | 0.09% | New | 2,670,000 | $3.3M |
| Sphera Funds Management LTD. | 0.39% | Add +6.3% | 1,929,297 | $2.4M |
| Ally Bridge Group (NY) LLC | 1.07% | Add +50.3% | 1,592,605 | $2.0M |
| Altium Capital Management LLC | 0.22% | New | 581,395 | $727K |
| Heights Capital Management, Inc. | 0.38% | — | 386,894 | $484K |
| Bank of Montreal | 0.00% | No change | 30,366 | $40K |
| Affinity Asset Advisors, LLC | 0.01% | Reduce -88.5% | 30,643 | $38K |
| Ieq Capital, LLC | 0.00% | No change | 26,042 | $33K |
| Fiduciary Trust Co | 0.00% | No change | 20,008 | $25K |
| Scotia Capital Inc. | 0.00% | New | 12,122 | $15K |
| Claret Asset Management Corp | 0.00% | Add +4.6% | 11,330 | $14K |
| Sandy Spring Bank | 0.00% | No change | 3,300 | $4K |
| Bank of America Corp. | 0.00% | No change | 1,666 | $2K |
| Royal Bank of Canada | 0.00% | Add +4.6% | 746 | $1K |
| National Bank of Canada | 0.00% | Add +26.4% | 421 | $526 |
| TD Waterhouse Canada Inc. | 0.00% | No change | 133 | $163 |
| JPMorgan Chase & Co. | 0.00% | No change | 3 | $4 |
"% of holder's portfolio" is PMN's weight in each manager's 13F, not the share of Promis Neurosciences Inc. the manager owns.